Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV.

MLA

Mayer, Bryan T., et al. “Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV.” Pharmaceutics, vol. 16, no. 5, May 2024, p. 594. EBSCOhost, https://doi.org/10.3390/pharmaceutics16050594.

APA

Mayer, B. T., Zhang, L., deCamp, A. C., Yu, C., Sato, A., Angier, H., Seaton, K. E., Yates, N., Ledgerwood, J. E., Mayer, K., Caskey, M., Nussenzweig, M., Stephenson, K., Julg, B., Barouch, D. H., Sobieszczyk, M. E., Edupuganti, S., Kelley, C. F., McElrath, M. J., & Gelderblom, H. C. (2024). Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV. Pharmaceutics, 16(5), 594. https://doi.org/10.3390/pharmaceutics16050594

Chicago

Mayer, Bryan T., Lily Zhang, Allan C. deCamp, Chenchen Yu, Alicia Sato, Heather Angier, Kelly E. Seaton, et al. 2024. “Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV.” Pharmaceutics 16 (5): 594. doi:10.3390/pharmaceutics16050594.